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In a population-based prospective study of 49850 Japanese men, body mass index and height were not significantly associated with
risk of prostate cancer (311 cases), although small positive effects could not be ruled out in advanced cases (91 cases).
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The prostate cancer rate in Japan is much lower than in Western
populations (Ajiki et al, 2004), but for reasons that are unclear.
Endogenous hormones such as testosterone and insulin-like
growth factor-I (IGF-I) are associated with prostate cancer (Kaaks
et al, 2000), and also with height and body mass index (BMI).
Studies of prostate cancer risk in relation to BMI and height have
been inconsistent (IARC, 2002), partly because of differences in the
range of BMI and height values used. One reason for the low
incidence of prostate cancer in Japan may be the small proportion
of tall men and men with a high BMI.
We conducted a population-based prospective study of BMI and
height in relation to the risk of prostate cancer in Japanese men.
MATERIALS AND METHODS
The Japan Public Health Centre-based Prospective Study (JPHC
study), initiated in 1990 for Cohort I and in 1993 for Cohort II, has
been described in detail previously (Otani et al, 2005). Cohort I
included those aged 40–59 years resident in four public health
centre (PHC) areas, and Cohort II those aged 40–69 years resident
in six PHC areas. We enrolled men who provided valid responses
to a self-administered questionnaire (77%), and excluded men with
history of prostate cancer (n¼3). Finally, a population-based
cohort of 49850 men was established.
The self-administered questionnaire asked about current height,
body weight (thereby providing BMI), various lifestyle factors
and medical history. We examined the correlation between data
recorded in health check-ups and self-reported data. Spearman’s
correlation coefficients were 0.93 for height and 0.91 for BMI,
respectively; the self-reported data were considered appropriate
for use in the present study.
Subjects were followed from the baseline survey until 31
December 2003, during which time a total of 311 newly diagnosed
prostate cancer cases were identified. Eight per cent of the subjects
moved out of a study area and 0.2% were lost to follow-up during
the study period.
The relative risk (RR) and 95% confidence interval (CI) of
prostate cancer according to BMI and height were calculated by
the Cox proportional hazards model, adjusting for potential
confounders. We conducted additional analyses limited to the 91
advanced cases, with extraprostatic or metastatic spread. Of the
remaining cases, 179 were organ localised and 41 (13.2% of total)
were of undetermined stage.
RESULTS
Body mass index and height were higher in young and married
men than in others. Although the proportion of current smokers
decreased with increasing BMI, it positively increased with
increasing height. A family history of prostate cancer was not
associated with BMI or height.
Table 1 presents RRs in relation to BMI and height for total
cases and for each stage of diagnosis. Weak associations were
found between BMI and total prostate cancer (RR¼1.31 95%
CI¼0.97–1.76 for X25 vs p21.9, P for trend¼0.057). However,
multivariate RRs were attenuated (P for trend¼0.13). When we
analysed according to stage of disease, BMI was not associated
with risk for organ-localised prostate cancer (RR¼1.18 for X25 vs
p21.9), although RR tended to increase with increasing BMI for
advanced cases (RR¼1.38 for X25 vs p21.9). In multivariate
analysis, the degrees of attenuation in both localised cancer and
advanced cancer were similar (data not shown). We also found
no association between height and total prostate cancer (P for
trend¼0.45). In advanced cases, the higher categories tended to be
associated with increased risk of prostate cancer.
DISCUSSION
To our knowledge, this is the first prospective study to report an
association between prostate cancer and anthropometry in
Japanese.
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yThe absence of a consistent association between BMI, height and
prostate cancer in the present study is in agreement with previous
results from Asia (Severson et al, 1988; Hsing et al, 2000), but not
with others from Western countries (Kaaks et al, 2000). The effects
of anthropometry therefore seem to differ by country and
ethnicity. The differences according to country may be due to
ethnic variation in hormonal factors. For example, the hormone
level of androstane-3a-17b-diol glucuronide, an index of 5a-
reductase activity, and IGF-binding protein-3, which modulates
the effect of IGF-1, differs according to ethnicity (Platz et al, 1999;
Wu et al, 2001). A second possibility is that the variation in BMI
and height among the present subjects was too small to reveal
associations with prostate cancer. It is therefore interesting to
contemplate whether an association between BMI or height and
prostate cancer would have been detected if more subjects with a
greater BMI or height had been enrolled.
We also found slightly stronger associations for advanced than
localised disease, although this interpretation was hampered by
the small number of cases. Obesity is associated with higher
circulating levels of leptin, and leptin has angiogenic activity
that correlates with metastasis (Kaaks et al, 2000; Ribeiro et al,
2004).
In conclusion, our results provide no evidence that BMI and
height are associated with the risk of prostate cancer among a
relatively lean population. However, they do not rule out the
possibility that anthropometry is associated with prostate cancer
in advanced cases.
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Table 1 Relative risk of prostate cancer for body mass index (BMI) and height at baseline: JPHC study, 1990–2003
BMI (kg/m
2)
p21.9 22.0–23.4 23.5–24.9 X25.0 P for trend
All cases
Number of cases 94 66 64 87
Person-years of follow-up 161231 116233 107654 147806
Crude incidence rate
a 58.3 56.8 59.4 58.9
Age- and area-adjusted relative risk 1.00 1.05 1.20 1.31 0.057
95% CI Reference 0.77–1.44 0.87–1.65 0.97–1.76
Multivariate relative risk
b 1.00 1.04 1.19 1.24 0.13
95% CI Reference 0.76–1.43 0.86–1.63 0.92–1.67
Localised cases
Number of cases 53 43 33 50
Multivariate relative risk
b 1.00 1.16 1.04 1.18
95% CI Reference 0.78–1.74 0.67–1.60 0.79–1.76 0.51
Advanced cases
Number of cases 28 16 20 27
Multivariate relative risk
b 1.00 0.90 1.33 1.38 0.16
95% CI Reference 0.49–1.67 0.75–2.37 0.80–2.39
Height (cm)
p159 160–164 164–167 X168 P for trend
All cases
Number of cases 80 98 75 58
Person-years of follow-up 110069 140842 127309 154704
Crude incidence rate
a 72.7 69.6 58.9 37.5
Age- and area-adjusted relative risk 1.00 1.30 1.30 1.17 0.33
95% CI Reference 0.97–1.76 0.94–1.80 0.82–1.66
Multivariate relative risk
c 1.00 1.27 1.24 1.08 0.45
95% CI Reference 0.93–1.73 0.88–1.75 0.73–1.59
Localised cases
Number of cases 51 57 46 25
Multivariate relative risk
c 1.00 1.13 1.18 0.71 0.48
95%CI Reference 0.76–1.68 0.76–1.82 0.41–1.22
Advanced cases
Number of cases 21 30 20 20
Multivariate relative risk
c 1.00 1.57 1.31 1.51 0.38
95% CI Reference 0.88–2.81 0.68–2.53 0.74–3.10
CI¼confidence interval; JPHC¼Japan Public Health Centre-based Prospective Study.
aNumber of prostate cancer cases per 100000 person-years.
bAdjusted for age, area,
smoking status, family history of prostate cancer and marital status.
cAdjusted for age, area, smoking status, family history of prostate cancer, marital status and body weight.
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Koizumi, Y Sano, and I Hashimoto, Iwate Prefectural Ninohe
Public Health Center, Ninohe; Y Miyajima, N Suzuki, S Nagasawa
and Y Furusugi, Akita Prefectural Yokote Public Health Center,
Yokote; H Sanada, Y Hatayama, F Kobayashi, H Uchino, Y Shirai,
T Kondo, R Sasaki, Y Watanabe and Y Miyagawa, Nagano
Prefectural Saku Public Health Center, Saku; Y Kishimoto, E
Takara, T Fukuyama, M Kinjo, M Irei and H Sakiyama, Okinawa
Prefectural Chubu Public Health Center, Okinawa; K Imoto, H
Yazawa, T Seo, A Seiko, F Ito and F Shoji, Katsushika Public Health
Center, Tokyo; A Murata, K Minato, K Motegi and T Fujieda,
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Abe, M Katagiri and M Suzuki, Niigata Prefectural Kashiwazaki
and Nagaoka Public Health Center, Kashiwazaki and Nagaoka; M
Doi, A Terao and Y Ishikawa, Kochi Prefectural Chuo-higashi
Public Health Center, Tosayamada; H Sueta, H Doi, M Urata, N
Okamoto and F Ide, Nagasaki Prefectural Kamigoto Public Health
Center, Arikawa; H Saldyama, N Onga and H Takaesu, Okinawa
Prefectural Miyako Public Health Center, Hirara; F Horii, I Asano,
H Yamaguchi, K Aoki, S Maruyama and M Ichii, Osaka Prefectural
Suita Public Health Center, Suita; S Matsushima and S Natsukawa,
Saku General Hospital, Usuda; M Akabane, Tokyo University of
Agriculture, Tokyo; M Konishi and K Okada, Ehime University.
Toon; H Iso, Osaka University, Suita; Y Honda and K Yamagishi,
Tsukuba University, Tsukuba; H Sugimura, Hamamatsu Univer-
sity, Hamamatsu; Y Tsubono, Tohoku University, Sendai; M
Kabuto, National Institute for Environmental Studies, Tsukuba; S
Tominaga, Aichi Cancer Center Research Institute, Nagoya; M Iida
and W Ajiki, Osaka Medical Center for Cancer and Cardiovascular
Disease, Osaka; S Sato, Osaka Medical Center for Health Science
and Promotion, Osaka; N Yasuda, Kochi University, Nankoku; S
Kono, Kyushu University, Fukuoka; K Suzuki, Research Institute
for Brain and Blood Vessels Akita, Akita; Y Takashima, Kyorin
University, Mitaka; E Maruyama, Kobe University, Kobe; the late
M Yamaguchi, Y Matsumura, S Sasaki and S Watanabe, National
Institute of Health and Nutrition, Tokyo; T Kadowaki, Tokyo
University, Tokyo; Y Kawaguchi, Tokyo Medical and Dental
University, Tokyo; H Shimizu, Sakihae Institute, Gifu.
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